24932 Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices 

state, tribal, local, or territorial health 

agencies, or non-governmental 

organizations), focusing on public 

health or health/healthcare. 

When PHAP originated in 2007, the 

program focused on increasing 

recruitment and enrollment; to date, 

there has been limited systematic 

assessment of the program. As a result, 

one current program priority is focused 

on documenting program outcomes to 

inform refinements to program 

processes and activities, demonstrate 

program impact, and inform decision 

making about future program direction. 

The purpose of this information 

collection request (ICR) is to gain 

approval to follow alumni career 

progression following participation in 

PHAP. The ICR will enable the program 

to demonstrate evidence of program 

outcomes, specifically to document how 

many alumni are retained as members of 

the public health workforce, where 

alumni are employed, what topical and 

functional public health areas alumni 

support (e.g., chronic disease, infectious 

disease, assessment, communications, 

etc.), to what extent alumni support the 

capabilities of public health agencies at 

the federal, state, territorial, local, tribal, 

and non-governmental organizational 

levels, and to what extent PHAP has 

influenced alumni career paths (if at 

all). Information will be used to answer 

key program assessment questions, 

specifically: ‘‘Is PHAP a quality 

program?’’, ‘‘Is PHAP an effective 

program?’’, and ‘‘What is the impact of 

PHAP?’’ 

CDC will administer the PHAP 

Alumni Assessment at two different 

time points (1 year post-graduation, and 

3 years post-graduation) to PHAP 

alumni. Assessment questions will 

remain consistent at each 

administration (i.e., 1 year, or 3 years 

post-PHAP graduation). The language, 

however, will be updated for each 

assessment administration to reflect the 

appropriate time period. It is estimated 

that there will be no more than 480 

respondents (160 respondents annually) 

over the course of the three year 

approval period. Assessments will be 

administered electronically; each 

alumnus will receive an embedded link 

in an email invitation that is unique to 

that alumnus; each alumnus will only 

have access to his/her link to the 

assessment Web site. The total 

estimated burden is 8 minutes per 

respondent per assessment. The total 

annualized estimated burden is 21 

hours. 

There are no costs to respondents 

except their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

PHAP Alumni .................................................. PHAP Alumni Assessment ............................. 160 1 8/60 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–10183 Filed 4–30–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number CDC–2015–0021, NIOSH 

153–C] 

Request for the Technical Review of 19 

Draft Skin Notation Assignments and 

Skin Notation Profiles 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for information and 

comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) is 

conducting a public review of the draft 

skin notations and supporting technical 

documents entitled, Skin Notations 

Profiles, for 19 chemicals. NIOSH is 

requesting technical reviews of the draft 

Skin Notation Profiles. 

DATES: Electronic or written comments 

must be received by June 30, 2015. 

ADDRESSES: You may submit comments, 

identified by CDC–2015–0021 and 

docket number NIOSH 153–C, by any of 

the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Institute for 

Occupational Safety and Health, NIOSH 

Docket Office, 1090 Tusculum Avenue, 

MS C–34, Cincinnati, Ohio 45226–1998. 

Instructions: All information received 

in response to this notice must include 

the agency name and docket number 

[CDC–2015–0021; NIOSH 153–C]. All 

relevant comments received will be 

posted without change to 

www.regulations.gov, including any 

personal information provided. All 

electronic comments should be 

formatted as Microsoft Word. For access 

to the docket to read background 

documents or comments received, go to 

www.regulations.gov. All information 

received in response to this notice will 

also be available for public examination 

and copying at the NIOSH Docket 

Office, 1150 Tusculum Avenue, Room 

155, Cincinnati, OH 45226–1998. 

FOR FURTHER INFORMATION CONTACT: 

Naomi Hudson, NIOSH Robert A. Taft 

Laboratories, MS–C32, 1190 Tusculum 

Ave., Cincinnati, OH 45226. (513)533– 

8388 (not a toll free number). 

SUPPLEMENTARY INFORMATION: This 

review follows the publication of 22 

Skin Notation Profiles, Docket Number 

NIOSH 153–A http://www.cdc.gov/

niosh/docket/archive/docket153A.html 

and the external review of an additional 

25 Skin Notation Profiles, Docket 

Number NIOSH 153–B http://

www.cdc.gov/niosh/docket/archive/

docket153B.html. To facilitate the 

review of these documents, NIOSH 

requests that the following questions be 

taken into consideration for each Skin 

Notation Profile: 

1. Does this document clearly outline 

the systemic health hazards associated 

with exposures of the skin to the 

chemical? If not, what specific 

information is missing from the 

document? 

2. If the SYS or SYS (FATAL) 

notations are assigned, are the rationale 

and logic behind the assignment clear? 

If not assigned, is the logic clear why it 

was not (e.g., insufficient data, no 

identified health hazard)? 

3. Does this document clearly outline 

the direct (localized) health hazards 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices 24933 

associated with exposures of the skin to 

the chemical? If not, what specific 

information is missing from the 

document? 

4. If the DIR, DIR (IRR), or DIR (COR) 

notations are assigned, are the rationale 

and logic behind the assignment clear? 

If not assigned, is the logic clear why it 

was not (e.g., insufficient data, no 

identified health hazard)? 

5. Does this document clearly outline 

the immune-mediated responses 

(allergic response) health hazards 

associated with exposures of the skin to 

the chemical? If not, what specific 

information is missing from the 

document? 

6. If the SEN notation is assigned, are 

the rationale and logic behind the 

assignment clear? If not assigned, is the 

logic clear why it was not (e.g., 

insufficient data, no identified health 

hazard)? 

7. If the ID (SK) or SK were assigned, 

are the rationale and logic outlined 

within the document? 

8. Are the conclusions supported by 

the data? 

9. Are the tables clear and 

appropriate? 

10. Is the document organized 

appropriately? If not, what 

improvements are needed? 

11. Are you aware of any scientific 

data reported in governmental 

publications, databases, peer-reviewed 

journals, or other sources that should be 

included within this document? 

In 2009, NIOSH published Current 

Intelligence Bulletin (CIB) 61—A 

Strategy for assigning New NIOSH Skin 

Notations [NIOSH 2009–147; http://

www.cdc.gov/niosh/docs/2009-147/

pdfs/2009-147.pdf]. The CIB presents a 

strategic framework that is a form of 

hazard identification that has been 

designed to do the following: 

1. Ensure that the assigned skin 

notations reflect the contemporary state 

of scientific knowledge 

2. Provide transparency behind the 

assignment process 

3. Communicate the hazards of 

chemical exposures of the skin 

4. Meet the needs of health 

professionals, employers, and other 

interested parties in protecting workers 

from chemical contact with the skin. 

This strategy involves the assignment 

of multiple skin notations for 

distinguishing systemic (SYS), direct 

(DIR), and sensitizing (SEN) effects 

caused by exposure of skin (SK) to 

chemicals. Chemicals that are highly or 

extremely toxic and may be potentially 

lethal or life-threatening following 

exposures of the skin are designated 

with the systemic subnotation (FATAL). 

Potential irritants and corrosive 

chemicals are indicated by the direct 

effects subnotations (IRR) and (COR), 

respectively. Thus with the new 

strategy, chemicals labeled as SK: SYS 

are recognized to contribute to systemic 

toxicity through dermal absorption. 

Chemicals assigned the notation SK: 

SYS (FATAL) have been identified as 

highly or extremely toxic and have the 

potential to be lethal or life-threatening 

following acute contact with the skin. 

Substances identified to cause direct 

effects (i.e., damage or destruction) to 

the skin limited to or near the point of 

contact are labeled SK: DIR, and those 

resulting in skin irritation and corrosion 

at the point of contact are labeled as SK: 

DIR (IRR) and SK: DIR (COR), 

respectively. The SK: SEN notation is 

used for substances identified as 

causing or contributing to allergic 

contact dermatitis (ACD) or other 

immune-mediated responses, such as 

airway hyper reactivity (asthma). 

Candidate chemicals may be assigned 

more than one skin notation when they 

are identified to cause multiple effects 

resulting from skin exposure. For 

example, if a chemical is identified as 

corrosive and also contributes to 

systemic toxicity, it will be labeled as 

SK: SYS–DIR (COR). When scientific 

data for a chemical indicate that skin 

exposure does not produce systemic, 

direct, or sensitizing effects, the 

compound will be assigned the notation 

(SK). The ID(SK) notation is assigned to 

indicate that insufficient data on the 

health hazards associated with skin 

exposure to a substance exist at the time 

of the review to determine whether the 

chemical has the potential to act as a 

systemic, direct, or sensitizing agent. 

The ND notation indicates that a 

chemical has not been evaluated by the 

strategy outlined in this CIB and that the 

health hazards associated with skin 

exposure are unknown. 

Historically, skin notations have been 

published in the NIOSH Pocket Guide to 

Chemical Hazards [NIOSH 2005–149, 

http://www.cdc.gov/niosh/npg/]. This 

practice will continue with the NIOSH 

skin notation assignments for each 

evaluated chemical being integrated as 

they become available. A support 

document called a Skin Notation Profile 

has been developed for each evaluated 

chemical. NIOSH submitted the first 

group of Skin Notation Profiles for 

external review in 2010 [75 FR 22148] 

and published the finalized reports in 

2011 [http://www.cdc.gov/niosh/topics/

skin/skin-notation_profiles.html]. The 

Skin Notation Profile for a chemical is 

intended to provide information 

supplemental to the skin notation, 

including a summary of all relevant data 

used to aid in determining the hazards 

associated with skin exposures. 

NIOSH seeks comments on the draft 

skin notation assignments and Skin 

Notation Profiles for 19 chemicals. The 

draft Skin Notation Profiles were 

developed to provide the scientific 

rationale behind the hazard-specific 

skin notation (SK) assignments for the 

following chemicals: 

Substance(s) 

Trichloroethylene ......................................................................................................................................................................... (CAS #79–01–06) 

Acrylic acid .................................................................................................................................................................................. (CAS #79–10–7) 

Tetraethyl lead ............................................................................................................................................................................. (CAS #78–00–2) 

Tetramethyl lead .......................................................................................................................................................................... (CAS #75–74–1) 

2-Hydropropyl acrylate ................................................................................................................................................................ (CAS #999–61–1) 

Dimethyl sulfate ........................................................................................................................................................................... (CAS #77–78–1) 

Arsenic ......................................................................................................................................................................................... (CAS #7440–38–2) 

Pentachlorophenol ....................................................................................................................................................................... (CAS #87–86–5) 

Dichlorvos .................................................................................................................................................................................... (CAS #62–73–7) 

Heptachlor ................................................................................................................................................................................... (CAS #76–44–8) 

Disulfoton ..................................................................................................................................................................................... (CAS #298–04–4) 

Atrazine ....................................................................................................................................................................................... (CAS #1912–24–9) 

Morpholine ................................................................................................................................................................................... (CAS #110–91–8) 

EPN ............................................................................................................................................................................................. (CAS #2104–64–5) 

Sodium fluoroacetate .................................................................................................................................................................. (CAS #62–74–8) 

Chlorinated camphene ................................................................................................................................................................ (CAS #8001–35–2) 

Dioxathion .................................................................................................................................................................................... (CAS#78–34–2) 

Catechol ...................................................................................................................................................................................... (CAS #120–80–9) 

mstockstill on DSK4VPTVN1PROD with NOTICES

24934 Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices 

Substance(s) 

1-Bromopropane .......................................................................................................................................................................... (CAS #106–94–5) 

Each Skin Notation Profile provides a 

detailed summary of the health hazards 

of skin contact and rationale for the 

proposed SK assignment with the 

chemical(s) of interest. 

Dated: April 22, 2015. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2015–10289 Filed 4–30–15; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10261, CMS– 

10185 and CMS–2540–10] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services. 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

any of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments must be received by 

June 30, 2015: 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number llll, Room C4–26– 

05, 7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ Web site address at 

http://www.cms.hhs.gov/

PaperworkReductionActof1995. 

2. Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov. 

3. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

Reports Clearance Office at (410) 786– 

1326. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10261 Part C Medicare 

Advantage Reporting Requirements and 

Supporting Regulations 

CMS–10185 Medicare Part D 

Reporting Requirements and 

Supporting Regulations 

CMS–2540 Skilled Nursing Facility 

and Skilled Nursing Facility Health 

Care Complex Cost Report Form 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Part C Medicare 

Advantage Reporting Requirements and 

Supporting Regulations; Use: There are 

a number of information users of Part C 

reporting data, including our central 

and regional office staff that use this 

information to monitor health plans and 

to hold them accountable for their 

performance, researchers, and other 

government agencies such as the 

Government Accounting Office. Health 

plans can use this information to 

measure and benchmark their 

performance. Form Number: CMS– 

10261 (OMB Control Number 0938– 

1054); Frequency: Yearly and semiannually; Affected Public: Private sector 

(business or other for-profits); Number 

of Respondents: 561; Total Annual 

Responses: 3,508; Total Annual Hours: 

201,503. (For policy questions regarding 

this collection contact Terry Lied at 

410–786–8973). 

2. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Medicare Part D 

Reporting Requirements and Supporting 

Regulations; Use: To ensure quality 

provision of the Medicare Prescription 

Drug Benefit to beneficiaries, the 

collected information will serve as an 

integral resource for oversight, 

monitoring, compliance, and auditing 

activities. Sponsors should retain 

documentation and data records related 

to their data submissions. Data will be 

validated, analyzed, and utilized for 

trend reporting. For CY 2016 reporting, 

the following sections will be reported 

mstockstill on DSK4VPTVN1PROD with NOTICES